Comparative efficacy of Gan & Lee insulin aspart (GL-ASP) and EU-marketed insulin aspart (NN-ASP), when combined with metformin, in patients with diabetes mellitus: Post-hoc analyses from a multicenter, randomized, open-label, controlled clinical trial

被引：0
|
作者：
Yao, Jun [1 ]
Wang, Damei [2 ]
Guo, Xiaohui [1 ]
机构：
[1] Peking Univ First Hosp, 8 Xishiku St, Beijing 100034, Peoples R China
[2] Gan & Lee Pharmaceut, 8 Nanfeng Xiyi Rd, Beijing 101109, Peoples R China
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2022年 / 128卷
关键词：
Efficacy; insulin aspart; metformin; safety;
D O I：
10.1016/j.metabol.2021.155076
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0122
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 2 条
  • [1] Comparative efficacy and safety of two insulin aspart formulations (Rapilin and NovoRapid) when combined with metformin, for patients with diabetes mellitus: a multicenter, randomized, open-label, controlled clinical trial
    Yao, Jun
    Guo, Xiaohui
    Sun, Li
    Han, Ping
    Lv, Xiaofeng
    Zhang, Xiuzhen
    Mo, Zhaohui
    Yang, Wenying
    Zhang, Lihui
    Wang, Zhanjian
    Zhu, Lvyun
    Li, Quanmin
    Yang, Tao
    Wang, Wenbo
    Xue, Yaoming
    Shi, Yongquan
    Lu, Juming
    Peng, Yongde
    Zhang, Fan
    Yan, Dewen
    Wang, Damei
    Yu, Xuefeng
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (11) : 1797 - 1806
  • [2] Treatment efficacy and glucose variability control of exenatide versus biphasic insulin aspart 30 in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicenter, randomized, open-label, parallel study
    Liu, Xiangyang
    Ji, Qiuhe
    Yang, Wenjuan
    Liu, Jianrong
    Gao, Xiling
    He, Qingzhen
    Ma, Kaiyan
    Tian, Zhufang
    Xie, Xuan
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2018, 34
1